Nabriva Therapeutics PLC reports results for the quarter ended in September - Earnings Summary

Nabriva Therapeutics

10/11/2022 22:45

* Nabriva Therapeutics PLC  NBRV.OQ  reported a quarterly
adjusted
loss of $4.21​​ per share for the quarter ended in September.
The mean expectation of two analysts for the quarter was for a
loss of $4.02 per share.
    * Revenue rose 3.3% to $9.15 million from a year ago;
analysts
expected $10.68 million. 
    * Nabriva Therapeutics PLC's reported EPS for the quarter
was a
loss of $4.21​.
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Nabriva Therapeutics PLC shares had risen by 1.4% this
quarter and lost 85.9% so far this year.
    * The company reported a quarterly loss of $11.51 million.
    * Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $18.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 10:45 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -4.02          -4.21          Missed
 Jun. 30 2022      -5.00          -4.50          Beat
 Mar. 31 2022      -4.75          -5.00          Missed
 Dec. 31 2021      -4.75          -6.00          Missed